This year, six biosimilars for the top-selling medicine, Humira, will enter the market, with the first launching on January 31, 2023. Increased competition from biosimilars can drive down costs. But experts argue that insurers and pharmacy benefit...
This year, six biosimilars for the top-selling medicine, Humira, will enter the market, with the first launching on January 31, 2023. Increased competition from biosimilars can drive down costs. But experts argue that insurers and pharmacy benefit managers will receive those savings – not patients.
On this episode, hear from pharmacists, health economists, patient advocates, and health care experts about what biosimilar milestones 2023 will bring for patients. Plus, how to fix the system so that patients get the cost-savings they need.
And listen to Brandi Privitera’s story, where she discusses her health care journey with fibromyalgia and lends advice to fellow parents who live with a chronic illness.
Dr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public Interest
Vickie Wilkerson, Patient Advocate
Kristy Birchard, Patient Correspondent
The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?
Drop us a line: firstname.lastname@example.org
The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising, nor do the views and opinions stated on this show reflect the opinions of a guest’s current or previous employers.